Cipla Limited CC-Mar25.pdf · 2025-05-13
Just I want to know that the way you have mentioned as far as your EBITDA guidance the -- as far as overall revenue for next FY '26, can we expect that your top line is going to go in the range of 7% to 9% kind of thing. The way you already mentioned that you are going to continue the same growth trajectory. So I'm just talking about the overall growth, will be in the same range as far as top line revenue is concerned?
Okay. And my second question, the way, sir, the U.S. in which the situation somewhere right now evolving related to pharma-related aspects, can you throw some light that it is going to affect the -- our U.S. business or we do not have any kind of challenges due to that?